Company intelligence / Profile preview
Steminent Biotherapeutics
Taipei, Taipei City, Taiwansteminent.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Stemchymal®, the lead allogeneic adipose-derived mesenchymal stem cell product, has completed Phase 2 trials in Taiwan and Japan for spinocerebellar ataxia. The trials demonstrated positive results, including significant clearance of mutant Ataxin 3 protein and improved motor function in preclinical models. The product has received Orphan Drug Designation from both the US FDA and Japan PMDA for SCA treatment.
- Therapeutic areas
- ImmunologyNeurologyCardiovascular
- Modalities
- Mesenchymal stem cell therapyCell therapyAllogeneic stem cell therapyAdipose-derived mesenchymal stem cell therapy
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
03
Partnerships
REPROCELL (Japan development/licensing partner)SCM Lifescience (South Korea licensing partner)
Beyond the preview
Go deeper on Steminent Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Steminent Biotherapeutics.